Day: March 24, 2022

Virtusa Vax Manager solution helps companies track employee vaccination status and testing results for return to the office

SOUTHBOROUGH, Mass., March 24, 2022 (GLOBE NEWSWIRE) — Virtusa Corporation today announced that its Virtusa Vax Manager is available to provide businesses with an easy way to track employee vaccination status. The COVID-19 vaccine tracker and return to office capabilities of Virtusa Vax Manager can be built rapidly, and is easily configurable on technology from Pegasystems, the software company that crushes business complexity, to help companies stay compliant with emerging regulations, while ensuring the wellbeing of all employees and easing the burden on HR staff.

The Department of Labor’s Occupational Safety and Health Administration (OSHA) in its recent press release mentioned that it continues to strongly encourage vaccination of workers against the continuing dangers posed by COVID-19 in the Workplace.

The Virtusa Vax Manager provides companies with all the capabilities needed to streamline the tracking process, reducing time to comply with company, state and/or federal mandates. Key features include:

• Vaccine Tracking: Capture vaccination details for employees such as number of doses and vaccine type, with an option to upload their vaccine card.
• Vaccine Exception Detail: Document vaccination exception details for employees with an option to upload supporting documentation.
• Return to Office Questionnaire: Collect health status information of employees, complete return to office questionnaires.
• Reports: Utilize various key reports for operational, executive, and federal requirements.
• Employee Health Assessment: Evaluate employee health status using prebuilt questionnaires, arranging work from home by providing necessary resources.

“With company and federal mandates upon us, companies are scrambling to figure out how to quickly and confidently track the vaccine status for every employee – without becoming distracted from day-to-day business,” said Anthony Lange, Senior Vice President of Healthcare and Life Sciences, Virtusa. “Even before the pandemic, we were designing systems capable of quickly gathering, validating, and sharing large amounts of sensitive health-related data. The new tracker is a great example of our collaborative efforts with Pega to quickly help clients address unexpected challenges.”

“As a Global Elite Partner, Virtusa is ideal to support this important initiative given their healthcare and life sciences expertise,” said Kelli Bravo, Global Vice President Healthcare and Life Sciences, Pega. “Enterprises need to be agile and ready to adapt to new regulations and mandates, and the tracker is designed with that in mind. The vaccine tracker is now available on the Pega Marketplace, and Virtusa is offering a complimentary consultation for our joint clients to help ensure seamless adoption and client success.”

The tracker, built on the Pega Healthcare Platform, integrates with existing human capital management (HCM) systems including Workday, SAP’s SuccessFactors and Oracle. In addition to streamlining the vaccination tracking process, the solution also provides the ability to run risk assessment questionnaires, access trend, operational, executive, and state and federal reports, workplace surveys, and correspondence to employees and stakeholders.

For more information visit: https://www.virtusa.com/solutions/vax-vaccine-management-solution

About Virtusa

Virtusa Corporation is a global provider of digital business strategy, digital engineering, and information technology (IT) services and solutions that help clients change, disrupt, and unlock new value through innovative engineering. Virtusa serves Global 2000 companies in Banking, Financial Services, Insurance, Healthcare, Communications, Media, Entertainment, Travel, Manufacturing, and Technology industries.

Virtusa helps clients grow their business with innovative products and services that create operational efficiency using digital labor, future-proof operational and IT platforms, and rationalization and modernization of IT applications infrastructure. This is achieved through a unique approach blending deep contextual expertise, empowered agile teams, and measurably better engineering to create holistic solutions that drive the business forward at unparalleled velocity enabled by a culture of cooperative disruption.

Virtusa is a registered trademark of Virtusa Corporation. All other company and brand names may be trademarks or service marks of their respective holders.

Media contact:

Matt Berry
Conversion Marketing
matt@conversionam.com

Easy check, evaluation and documentation of metering performance

FLEXIM AMV Image

FLEXIM AMV Image

BERLIN, March 24, 2022 (GLOBE NEWSWIRE) — With Advanced Meter Verification (AMV), FLEXIM offers a powerful tool for checks, evaluation and documentation of the performance of its FLUXUS ultrasonic flowmeters. FLUXUS measures the flow of liquids, gases, and steam, as well as liquid-based thermal energy flows. Measurements are performed non-intrusively with clamp-on ultrasonic transducers mounted on the outside of the pipe. Since the transducers do not come into direct contact with the medium flowing inside, they are not subject to wear and tear and operate practically maintenance-free. The acoustic measurement method provides meaningful diagnostic values that can be used to reliably assess the measurement quality. AMV reads this diagnostic data and compares it with an initial reference state stored in the transmitter. This gives the user the assurance that the flow measurement is working properly. If the measurement quality deteriorates, this is clearly indicated in the verification report. Trend analysis enables the predictive planning of maintenance work. Unexpected failures can therefore be avoided.

The easy and convenient on-site measurement validation minimizes the effort for calibration and maintenance. It requires no interruption of measurement and does not interfere with process operation. AMV is intuitive to use and can be carried out by the user or by FLEXIM service technicians.

Please watch our video and check out our websites for more information.

Homepage: https://www.flexim.com/us

Contact Us: https://www.flexim.com/us/contact-us

Video: https://youtu.be/t-ZNgLD9F_Y

News & Events: https://flexim.com/us/about-us/news-and-events

Contact:

Tiffany DeMayo   Global Director of Marketing

FLEXIM GmbH     tdemayo@flexim.com     www.flexim.com

Related Images

Image 1: FLEXIM AMV Image

This content was issued through the press release distribution service at Newswire.com.

Attachment

• FLEXIM AMV Image

Founded by a digital insurance veteran with a track record for spotting the latest insurtech and founders, the new VC firm’s investment philosophy prioritizes evolution over disruption

Markd VC

Markd VC

BOULDER, Colo., March 24, 2022 (GLOBE NEWSWIRE) — Markd, a new insurtech VC firm, announced today the close of its $100M debut fund. The $100M vehicle will be used to fund early- and growth-stage startups with the potential to propel the digital transformation of the insurance industry. Anchor investors in Fund 1 include Markd founder and managing partner Parker Beauchamp and an undisclosed industry partner.

Investment funding in the insurtech space reached new heights last year, raising a record high of more than $10.5 billion (USD).

“While this is great news for general market escalation, the investment funding hasn’t been evenly distributed, and as many as 95% of insurtechs did not experience a rise in investment support,” said Beauchamp. “Markd was founded to identify and support transformative insurance ideas of high-potential startups not getting the attention and funding they deserve. With ideas around the metaverse, blockchain, and everything in between, there are some remarkable founders primed to evolve the industry perpetually. We’re committed to seeking investment partners who not only provide capital but possess industry expertise to create, reinvent and innovate conventional insurance models.”

As CEO of INGUARD, an insurance and risk management firm serving clients in the U.S. and abroad, Parker has spent over 20 years distributing insurance digitally, has a deep understanding and connection with the legacy insurance environment and a pulse on the future technologies and distribution challenges. Markd will build on this expertise, network, and experience to identify investments with the potential to transform and continually meet the needs of today’s consumers.

“During the fintech innovation boom, traditional banking joined forces with apps, cryptocurrency, and more, which improved the industry for everyone involved,” said Beauchamp. “Momentum toward it being insurance industry’s turn continues to accelerate, and we’re eager to utilize our experience, connections, and resources to help founders create wins for themselves and their customers.”

The Markd team has worked and built in the insurance technology space for decades, bridging the gap between established insurance leaders and new school founders. Open to various insurance sectors, Markd focuses on investing in transformational founders with innovative ideas and ambition to follow through on their vision.

“We want to be there at the first spark of a great idea,” said Beauchamp. “We’re not a group of disconnected investors. We’re committed to leveraging our existing relationships, know-how, ideas, regulatory access, carriers, fulfillment, and distribution teams we’ve built to help startups get further faster so founders can keep more of their equity longer.”

About Markd

Markd is a venture capital company focused on funding and partnering with transformative insurtechs. It pays homage to the insurance industry’s legacy while helping design its future. Markd’s mission is to power substantial work and continually inspire more ideas to prevent hurt and loss.

About Parker Beauchamp

Parker Beauchamp is the founder and managing partner of Markd. A fifth-generation insurance professional with nearly 25 years in the industry, and an avid adventurer, he lives and breathes the probabilities and consequences of risks. He is also the CEO of INGUARD, a forward-thinking insurance and risk management firm that has distributed insurance digitally nationwide since the end of the 20th century.

Press Contact:

Jen Sharpe

jsharpe@gebencommunication.com

Related Images

Image 1: Markd VC

Markd Logo

This content was issued through the press release distribution service at Newswire.com.

Attachment

• Markd VC

Abstract: Triall will onboard the globally deployed eClinical platform of Crucial Data Solutions into the Triall ecosystem, offering clinical researchers around the world with access to Triall’s blockchain APIs that strengthen clinical trial data integrity, auditability, and interoperability.

Featured Image for Triall

Featured Image for Triall

MAARSSEN, Netherlands, March 24, 2022 (GLOBE NEWSWIRE) — Triall, a tokenized platform for blockchain-enabled clinical trial technology, has partnered with Crucial Data Solutions (CDS), an eClinical software provider that offers a range of specialized applications for clinical trial data collection and management. Over the past decade, CDS has been a proven and leading innovator in the eClinical software industry, having implemented its eClinical solutions in over 7,000 clinical trials worldwide.

As part of this partnership, Triall will integrate its blockchain APIs with the eClinical solutions of CDS, realizing the world’s first end-to-end platform of eClinical solutions powered by blockchain. The platform covers all core clinical trial functions to radically advance data integrity, auditability, and interoperability in the global clinical trials industry.

The landmark partnership is a major leap forward for Triall as it enables the company to innovate on top of a validated eClinical platform that is trusted by thousands of industry professionals globally. Offered as part of the Triall ecosystem, the eClinical solutions will apply blockchain to generate verifiable proof of the integrity of clinical trial data, documents, and processes. Moreover, Triall leverages Decentralized Identity technologies and Self-Sovereign Identity (SSI) standards to facilitate interoperability across clinical trial systems and activities.

The Triall-CDS partnership is fully geared towards offering a future-proof platform that fits with emerging trends in the clinical trial industry, including real-world data collection and decentralized trial designs, while optimizing efficiency and reliability.

The partnership also has wild implications for Triall’s platform native utility token TRL, which grows in utility with the expansion of Triall’s software stack. TRL is used to pay for all software offered within the Triall ecosystem and was launched last year after a successful crowdfunding campaign that raised 2.4 million USD from over 1,500 investors. Prior to its token launch, Triall developed and commercialized its blockchain-integrated document management system Verial eTMF, which marked the world’s first implementation of blockchain in live and running clinical trials.

“Both CDS and Triall share a common vision where patients and sponsors of clinical research expect and deserve improved data privacy, security, and accountability. This partnership brings the future forward by giving patients unprecedented confidence in knowing that their data is secure and their privacy is protected.” – Jeff Rogers, President at Crucial Data Solutions

“Clinical trials have become increasingly digital, data-driven, and decentralized. This underlines the need for an end-to-end eClinical platform that unifies and secures all essential trial activities and processes. We have found the ideal partner in CDS and are very excited to continue our journey together.” – Hadil Es-Sbai, CEO at Triall

About Triall
Triall brings Web3 to medical research by creating a digital ecosystem of blockchain-integrated software solutions that secure and streamline clinical trials. Triall’s solutions make clinical trials tamper-resistant and enable secure and efficient integrations between the many isolated systems and parties involved in clinical trial processes. Triall’s software is co-created with clinical trial professionals to ensure optimal user experience, solving actual industry pain points.

For inquiries, reach out to contact@triall.io

Visit the website: https://www.triall.io

About Crucial Data Solutions 
Founded in 2010, Crucial Data Solutions (CDS) provides the most innovative “low-code/no-code” data and clinical trial management technology on the market today. TrialKit, our cloud-based platform available via both a web and native mobile app, enables end-to-end clinical trial management for medical device, diagnostics, digital therapeutics, and biotechnology, companies of all sizes. Design and deploy validated studies in days not weeks using our intuitive study builder that requires no programming. Over 10,000 global users have leveraged the flexibility of TrialKit to deploy over 7,000 studies across all phases of development, including Verily (a subsidiary of Alphabet), ICON GPHS, FUEL Studios, Catalyst Clinical Research, SISCAPA Assay Technologies, CDx Diagnostics, and Optinose, and many more.

Visit the website: https://www.crucialdatasolutions.com

Related Images

Image 1

This content was issued through the press release distribution service at Newswire.com.

Attachment

• Featured Image for Triall

นครโฮจิมินห์ ประเทศเวียดนาม, March 24, 2022 (GLOBE NEWSWIRE) — PEB Steel Buildings Co., Ltd. (Pebsteel) บริษัทชั้นนำในอุตสาหกรรมการก่อสร้างเหล็กโดยใช้โครงสร้างสำเร็จรูป ได้เปิดตัวอัตลักษณ์ของแบรนด์ที่ปรับปรุงใหม่ออกสู่ตลาด การรีแบรนด์นี้สนับสนุนวิสัยทัศน์ระยะยาวของ Pebsteel ในการนำเสนอโซลูชันที่เป็นนวัตกรรม ยั่งยืน และคุ้มค่าแก่ลูกค้าในระหว่างขั้นตอนการพัฒนาใหม่

ภาคการก่อสร้างและอุตสาหกรรมคาดว่าจะฟื้นตัวอย่างแข็งแกร่งหลังเกิดโควิด-19 ซึ่งส่งผลให้เกิดความต้องการอย่างมากสำหรับอาคารเหล็กที่ใช้โครงสร้างสำเร็จรูป และสิ่งปลูกสร้างที่ทำจากเหล็ก จากข้อมูลของนักวิเคราะห์อุตสาหกรรมทั่วโลก ตลาดโลกสำหรับการก่อสร้างเหล็กที่ใช้โครงสร้างสำเร็จรูปนั้นคาดว่าจะเติบโตจาก 27,100 ล้านดอลลาร์สหรัฐในปี 2020 เป็น 49,100 ล้านดอลลาร์สหรัฐในปี 2026 ซึ่งมีอัตราการเติบโตของพอร์ตเฉลี่ยต่อปีแบบทบต้นอยู่ที่ 10.1% เอเชียแปซิฟิกเป็นตลาดที่เติบโตเร็วที่สุดสำหรับอาคารที่ใช้โครงสร้างสำเร็จรูปและสิ่งปลูกสร้างที่ทำจากเหล็ก อันเนื่องมาจากการพัฒนาอุตสาหกรรมอย่างรวดเร็วและการขยายตัวของเมืองในประเทศเศรษฐกิจเกิดใหม่

นอกจากนี้ อาคารที่ใช้โครงสร้างสำเร็จรูปยังได้รับความนิยมเพิ่มขึ้นในตลาดการก่อสร้างเนื่องจากมีข้อดีหลายประการ อาคารเหล่านี้มีประสิทธิภาพด้านการประหยัดต้นทุนและประหยัดพลังงานมากกว่าวิธีการก่อสร้างทั่วไป โกดัง อาคารสำนักงาน โรงเก็บเครื่องบิน… เป็นส่วนเล็ก ๆ ของอาคารที่ใช้โครงสร้างสำเร็จรูปซึ่งใช้ในสิ่งปลูกสร้างที่หลากหลาย

Pebsteel เป็นบริษัทที่ก่อตั้งมาอย่างยาวนานด้วยสถิติที่ชัดเจนในการให้บริการอาคารสำเร็จรูปและสิ่งปลูกสร้างที่ทำจากเหล็กจำนวน 6,000 แห่งในกว่า 50 ประเทศ โครงการที่โดดเด่นของ Pebsteel ได้แก่ โรงงาน Unilever ที่สูงที่สุดในอินโดนีเซียด้วยความสูง 68 เมตร โรงเก็บเครื่องบิน Lufthansa ในฟิลิปปินส์ที่มีระยะห่างระหว่างริมในของเสาถึงเสาที่ใหญ่ที่สุดถึง 128 เมตร และอาคารโกดัง FCB ที่ยาวที่สุดในประเทศไทย ซึ่งมีความยาวรวมหนึ่งกิโลเมตร Pebsteel ยังทำลายสถิติของตัวเองด้วยการสร้างอาคารสำนักงานสูง 14 ชั้นในกรุงมะนิลา เช่นเดียวกับการสร้างทางเดินโค้งที่ไม่เหมือนใครสำหรับโรงแรมและรีสอร์ต Okada Manila

Pebsteel ก่อตั้งขึ้นในปี ค.ศ. 1994 โดย Sami Kteily และ Adib Kouteli ในยุโรปร่วมกับผู้ถือผลประโยชน์ร่วมของญี่ปุ่น (Nippon Steel และ Okaya & Co., Ltd) Pebsteel ดำเนินงานในสำนักงานขายภูมิภาค 10 แห่งและมีสำนักงานใหญ่อยู่ในเวียดนาม Sami Kteily ประธานกรรมการบริหารของ Pebsteel กล่าวว่า: “การรีแบรนด์เป็นก้าวสำคัญของ Pebsteel หลังจาก 27 ปีของการพัฒนา Pebsteel ได้ตอกย้ำความเป็นผู้นำในฐานะผู้ให้บริการโซลูชันแบบครบวงจรสำหรับสิ่งปลูกสร้างที่ทำจากเหล็กและอาคารที่ทำจากเหล็กซึ่งใช้โครงสร้างสำเร็จรูป ท่ามกลางตลาดการก่อสร้างที่เปลี่ยนแปลงอย่างรวดเร็วนั้นเอง Pebsteel ก็ได้เปิดตัวแท็กไลน์แบรนด์ใหม่ นั่นคือ “โซลูชันอาคารที่ใช้โครงสร้างสำเร็จรูป” เพื่อสะท้อนถึงความทะเยอทะยานในการสร้างโซลูชันที่มีประสิทธิภาพสำหรับอนาคตที่รุ่งเรือง นอกจากนี้ บริษัทยังได้ปรับปรุงโลโก้เพื่อแสดงให้เห็นถึงความพยายามในการพัฒนาและก้าวไปสู่ความเจริญรุ่งเรืองร่วมกับลูกค้า พันธมิตร และพนักงาน”

ติดต่อสื่อมวลชน : marketing@pebsteel.com.vn

https://www.globenewswire.com/NewsRoom/AttachmentNg/f73e0d2a-94de-4cf7-905f-4097b942c582